India · Delayed Price · Currency is INR Mankind Pharma Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and profit grew year-over-year, driven by strong chronic therapy and export performance, while acute and OTC segments are recovering post-restructuring. Working capital and debt metrics improved, and management expects double-digit growth ahead.
-
Revenue grew 21% year-over-year in Q2 FY26, with EBITDA margin at 25%. BSV and exports drove strong growth, while GST disruptions and higher costs impacted margins. Guidance for full-year EBITDA margin and BSV growth is maintained, with recovery expected in H2.
-
Q1 FY26 saw 24.5% revenue growth and 23.8% EBITDA margin, with strong domestic and international performance, though net profit declined 17.4% due to higher finance and depreciation costs. Guidance for margins and growth remains unchanged, with BSV expected to accelerate in H2.
Fiscal Year 2025
-
Revenue grew 27% YoY in Q4 and 19% for FY25, with strong chronic and consumer healthcare performance. Adjusted EBITDA margin improved to 25.9% for FY25, and VSC integration is expected to drive further growth and synergies. Guidance remains robust for FY26.
-
Q3 and 9M FY25 saw strong revenue and margin growth, driven by BSV integration, chronic and OTC outperformance, and robust exports. Corrective actions in field force and leadership led to temporary volume softness but improved margins. Synergies from BSV and further margin expansion are expected.
-
Q2 FY25 saw 14% revenue growth and 27.7% EBITDA margin, driven by chronic and OTC segments, with BSV acquisition expanding specialty presence. Debt for the acquisition is set to be retired within three years through equity and asset sales, while double-digit growth and margin improvement are guided.
-
Q1 FY25 saw 12% revenue growth, 25.2% adjusted EBITDA margin, and strong cash generation. Chronic and consumer healthcare segments outperformed, while the BSV acquisition and Panacea integration are expected to drive future growth and margin expansion.